Oral GLP‑1 pill approved
The FDA has approved oral semaglutide as the first GLP‑1 pill for weight loss, a major change because patients can now take a daily tablet rather than an injection — and regulators flagged reduced cardiovascular events as part of the approval. The OASIS‑4 trial behind the decision enrolled 307 adults with obesity and reported a 13.6% mean weight loss at 64 weeks, and Novo Nordisk had planned a U.S. launch of the once‑daily pill earlier this year (ajmc.com).
Glucagon-like peptide-1 is a gut hormone that tells the brain “you’ve eaten” and slows how fast food leaves the stomach, so people feel full sooner and stay full longer. Drugmakers turned that signal into medicines, but the big sellers for obesity have mostly been weekly shots, not pills. (medicalnewstoday.com) The hard part about making this kind of medicine into a tablet is the stomach itself. Semaglutide is a peptide, which means digestive acids and enzymes can break it down before much of it gets into the bloodstream. (ajmc.com) Novo Nordisk already had an oral semaglutide tablet on the market for type 2 diabetes under the brand name Rybelsus. In October 2025, the Food and Drug Administration also cleared that diabetes tablet to reduce major cardiovascular events in high-risk adults with type 2 diabetes. (prnewswire.com) Now the same ingredient has crossed into obesity treatment in a different form and dose. The Food and Drug Administration approved Wegovy tablets on December 22, 2025, as the first oral glucagon-like peptide-1 medicine for chronic weight management in U.S. adults with obesity, or with overweight plus at least one weight-related condition. (ajmc.com) (prnewswire.com) The approval leaned on a study called OASIS 4, which enrolled 307 adults with obesity or overweight. At 64 weeks, average weight loss was 13.6% with the pill, and Novo Nordisk said the figure was about 17% in an analysis that counted only people who stayed on treatment. (ajmc.com) (prnewswire.com) The cardiovascular piece is part of why this drug line has become so central in obesity care. Novo Nordisk said the Wegovy brand is indicated for weight loss and is also proven to help prevent life-threatening cardiovascular events in adults with established cardiovascular disease and overweight or obesity. (prnewswire.com) A pill changes the routine even if the biology stays the same. Instead of learning injection technique and storing pens, patients can take a once-daily tablet, which opens the door for people who avoid obesity treatment because they do not want a needle. (ajmc.com) (appliedclinicaltrialsonline.com) Novo Nordisk said in December 2025 that U.S. launch would begin in early January 2026, with a 1.5 milligram starting dose priced at $149 per month before insurance or savings programs. The company also said the tablets would be produced in North Carolina with supply already on hand. (prnewswire.com) The market did not stay empty for long. By early April 2026, Eli Lilly had also won Food and Drug Administration approval for its own once-daily oral glucagon-like peptide-1 drug, orforglipron, sold as Foundayo, which means the first semaglutide pill did not just open a new category — it started a race. (ajmc.com) (healio.com)
